| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.022 | 0.9 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.024 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | -0.023 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |